TA-MΦs exhibit ovarian TAM phenotypic characteristics. (A) Analysis of CD14 and CD163 expression on freshly isolated ovarian tumor CD14⁺ cells (TAMs) and on healthy donor monocytes cultured for 5 days in CM without (MΦs) or with ovarian tumor ascites (TA-MΦs), or with the SNs of the 5637, A172, or HepG2 tumor-cell lines (SN-MΦs). (B) MΦs, TAMs, TA-MΦs, and SN-MΦs were stimulated for 48 hours with LPS before FACS analysis of CD86 and ILT3 expressions. (C) TAMs, MΦs, TA-MΦs, and SN-MΦs were stimulated for 48 hours with LPS before IL-10 and IL-12 quantification. Results are expressed in MFI (A,B) or in ng/mL or pg/mL (C), as means plus or minus SD of experiments performed with TAMs from 10 patients, or experiments performed with monocytes from 4 healthy donors treated either with 4 different ascites fluids or with tumor-cell supernatants. (D) MΦs, TAMs, and TA-MΦs were activated for 48 hours with LPS and incubated, in graded doses, with allogenic CD4⁺ T cells. (E) MΦs, TAMs, TA-MΦs, and DCs were stimulated for 48 hours with LPS and incubated with allogenic CD4⁺ T cells plus anti-CD3 mAb and IL-2. (D,E) [³H]-thymidine incorporation was measured on day 4. Results are expressed in cpm (D) or in variation of T-cell proliferation (E) as means plus or minus SD of experiments realized with TAMs and ascites of 5 ovarian cancer patients. *P < .05.